Illustration: Aïda Amer/Axios
Avalyn Pharma, a rare respiratory disease biotech, plans to raise as much as $212 million in an IPO.
Why it matters: Avalyn joins the growing group of biotechs testing the public markets this spring as big-ticket M&A lifts the sector.
